MultiplexDX
MultiplexDX is a Slovak-headquartered molecular diagnostics company that develops RNA-based multiplexed cancer tests, primarily Multiplex8+ for breast cancer, combining RNA FISH and RNA sequencing for personalized treatment selection, while also selling custom oligonucleotides and infectious disease diagnostics.
- Company typePrivate
- Founded2016
- HeadquartersGaithersburg, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What MultiplexDX does
MultiplexDX, Inc. is a private biotechnology company founded in 2016 and headquartered at the Comenius University Science Park in Bratislava, Slovakia, with a U.S. presence near the NIH and FDA in Gaithersburg, Maryland. The company develops proprietary multiplexed, RNA-based molecular diagnostic tests, anchored by the Multiplex8+ breast cancer test and the underlying mFISHseq platform, which combines RNA fluorescence in situ hybridization (FISH) visualization with RNA sequencing using laser-capture microdissection to deliver cross-validated, single-cell resolution molecular profiling of over 20,000 protein-coding and non-coding genes from FFPE tissue samples. Reported technical performance includes 93% accuracy on a 1,082-sample validation (versus traditional IHC), 98% target diagnostic accuracy for Multiplex8+, and predictive coverage for 33 FDA/EMA-approved therapies including chemotherapies, immunotherapies, and antibody-drug conjugates.
The company monetizes through three primary streams: (1) diagnostic services performed in its ISO-15189 accredited laboratory and delivered to cancer centers (B2B) and individual patients (B2C); (2) custom oligonucleotide synthesis sold on a quote basis to academic and biotech research customers worldwide; and (3) contract R&D funded through government and EU grants, including the €3 million EIC Accelerator award. Distribution relies on direct enterprise field sales targeting oncology institutions, supported by active participation in major conferences (SABCS, ASCO, ESMO) and a strong scientific publication track record. Customers include named clinical partners such as Východoslovenský onkologický ústav (Eastern Slovak Oncology Institute) and Agel Group's Mammary Center, alongside an academic customer base that includes NIH, Rockefeller University, Cornell, ETH Zurich, and Hadassah Medical Center. The company has expanded its platform into infectious disease diagnostics via the IVD-certified vDetect COVID-19 RT-qPCR kit and into neurodegenerative disease research through the Horizon Europe ADDIT-CE consortium.
MultiplexDX firmographics
Firmographics- Name
- MultiplexDX
- Legal name
- MultiplexDX, Inc.
- Website
- https://multiplexdx.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MultiplexDX is a Slovak-headquartered molecular diagnostics company that develops RNA-based multiplexed cancer tests, primarily Multiplex8+ for breast cancer, combining RNA FISH and RNA sequencing for personalized treatment selection, while also selling custom oligonucleotides and infectious disease diagnostics.
- Ownership category
- akta.pro rank
MultiplexDX industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
Keywords
Where MultiplexDX is headquartered
LocationHeadquarters
- HQ city
- Gaithersburg
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
MultiplexDX business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Services: ISO-15189 accredited laboratory providing diagnostic services to cancer centers (B2B) and patients (B2C). Revenue from breast cancer diagnostic testing services using Multiplex8+ platform.
- Custom Oligonucleotides: Sale of custom synthesized oligonucleotides including DNA, RNA, and modified variants. Products include qPCR probes, FISH probes, adapters, and specialty oligos for research and diagnostic applications.
- R&D Services and Grants: Contract research services funded by government and EU grants. Company started generating revenue of approximately €300k annually from subproduct sales since 2016.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Custom Oligonucleotide Synthesis - quote-based pricing |
| Other | Multi-year contract | Multiplex8+ Diagnostic Test - enterprise pricing |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
MultiplexDX product offering
Product offeringCore offering
MultiplexDX develops and delivers multiplexed molecular diagnostic products and services built on a proprietary RNA-based platform that cross-validates RNA fluorescence in situ hybridization (FISH) visualization with RNA sequencing. Its core offering, the Multiplex8+ breast cancer diagnostic test, analyzes over 20,000 protein-coding and non-coding genes from FFPE tissue samples, predicts response to 33 FDA/EMA-approved therapies, and targets 98% diagnostic accuracy. The company also sells custom oligonucleotides, provides RNA sequencing, RNA FISH, and NGS/bioinformatics services, and has developed the IVD-certified vDetect COVID-19 RT-qPCR kit.
Product overview
MultiplexDX offers a portfolio of molecular diagnostic products and services centered on its proprietary RNA-based technologies. The core product is Multiplex8+, a breakthrough breast cancer diagnostic test that combines RNA visualization (RNA FISH) and RNA sequencing technologies for comprehensive molecular profiling. Supporting services include custom oligonucleotide synthesis, RNA sequencing, RNA FISH analysis, and NGS bioinformatics. The company also developed the IVD-certified vDetect COVID-19 RT-qPCR diagnostic kit and continues expanding into other infectious disease diagnostics. The product portfolio is designed to eliminate cancer misdiagnosis through cross-validation of biomarkers using multiple independent quantitative technologies.
Differentiator
Problem solved
Functional benefit
Brands
- Multiplex8+: A breakthrough diagnostic test for breast cancer that combines RNA-based visualization and sequencing technologies to provide comprehensive molecular profiling of over 20,000 protein-coding and non-coding genes for personalized treatment planning.
- vDetect COVID-19 RT-qPCR
- mFISHseq
- AIpredict
Products and services
- Multiplex8+ Breast Cancer Diagnostic Test A laboratory diagnostic service that combines proprietary RNA FISH visualization with RNA sequencing to cross-validate breast cancer biomarkers, analyzing more than 20,000 protein-coding and non-coding genes from FFPE tissue samples. Provides a personalized molecular barcode and predicts response to 33 FDA/EMA-approved therapies including chemotherapies, antibody-drug conjugates (e.g., Trodelvy via Trop2), anti-angiogenic agents (Avastin via VEGF), and immunotherapy regimens. Targets 98% diagnostic accuracy and is offered to oncology centers, hospitals, and individual patients.
- vDetect COVID-19 RT-qPCR Diagnostic Kit Quantitative in vitro diagnostic test designed to detect SARS-CoV-2 coronavirus genetic information by RT-qPCR in nasopharyngeal swabs. IVD certified by the Slovak State Institute for Drug Control and intended for use in diagnostic laboratories.
- Custom Oligonucleotide Synthesis High-quality custom oligonucleotide synthesis service offering aptamers, siRNA, miRNA, antagomirs, qPCR probes, oligonucleotide triphosphates, barcoded pre-adenylated 3'-adapters, and multicolor in situ probes. Supports DNA, RNA, LNA, 2'-OMe, 2'-F, and phosphorothioate backbones at lengths up to 120 nt and synthesis scales from 5 nmol to 1 μmol. Quote-based pricing for academic, research, and biotech customers worldwide.
- Barcoded Pre-adenylated 3'-Adapters Specialized barcoded pre-adenylated 3'-adapters used in small RNA library preparations, PAR-CLIP experiments, and barcoded microRNA library generation workflows. Used by research groups at Rockefeller University, ETH Zurich, Hadassah Hebrew University Medical Center, and Weill Cornell Medicine for high-throughput screening and RNA ligation experiments.
- RNA Sequencing Service RNA sequencing service for gene expression analysis and molecular profiling of biological samples, delivered through MultiplexDX's laboratory capabilities and integrated with the company's bioinformatics pipeline.
- RNA FISH Service RNA fluorescence in situ hybridization service for visualization and quantification of RNA molecules at single-cell resolution with high specificity and stability, supporting biomarker visualization workflows for research and diagnostic applications.
- NGS & Bioinformatics Service Next-generation sequencing services combined with bioinformatics analysis for comprehensive genomic data interpretation, supporting customers across the RNA sequencing and RNA FISH service lines.
Quantifiable outcome
- 98% diagnostic accuracy for breast cancer (up from 50-70% with current methods)
- +6 more outcomes
Companies that use MultiplexDX
Customer profileNamed customers15 records
Segments5 records
Ideal customer profiles3 records
MultiplexDX technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature8 records
MultiplexDX partnerships and signals
Strategic signalPartnerships
20 partnerships are on record, tiered minor and core.
- Masaryk UniversityminorProject partner in ADDIT-CE organizing Soft Skills Workshop on AI-enhanced research tools.
- JIC (South Moravian Innovation Centre)minorProject partner in ADDIT-CE contributing to workshop organization and innovation support.
- BioVendor GroupminorHost venue for ADDIT-CE NeuroConnect Meetup in Brno. BioVendor Group is a project partner providing facilities and collaboration for AD research.
- Masaryk UniversitycoreCzech partner in ADDIT-CE consortium developing and validating innovative Alzheimer's disease diagnostics. Part of Czech-Slovak center of excellence for AD diagnostics.
- Slovak Academy of SciencescorePartner in ADDIT-CE consortium. Excellent scientific team identifying and quantifying new RNA biomarkers for cancer and other human diseases.
- GenetoncoreTop biotech company collaborating in ADDIT-CE consortium for Alzheimer's disease diagnostics innovation.
- BioVendorcoreTop biotech company and project partner in ADDIT-CE consortium. Hosted ADDIT-CE NeuroConnect Meetup at BioVendor Group facilities in Brno.
- Slovak Alzheimer SocietyminorSocietal actor partner in ADDIT-CE consortium representing patient and caregiver interests in Alzheimer's disease diagnostics development.
- Czech Alzheimer SocietyminorSocietal actor partner in ADDIT-CE consortium for Czech Republic.
- Memory CenterminorClinical partner in ADDIT-CE consortium providing expertise in memory disorders and brain aging research.
- Czech Brain Aging StudyminorResearch partner in ADDIT-CE consortium conducting brain aging studies.
- Ministry of Health of the Slovak RepubliccoreRegional government partner in ADDIT-CE consortium providing policy support and healthcare system integration for AD diagnostics implementation.
- JIC (South Moravian Innovation Centre)minorBusiness innovation center partner in ADDIT-CE consortium supporting innovation ecosystem development.
- Public Health Authority of the Slovak RepubliccorePartner in CoV-INFect project developing RT-qPCR and RT-LAMP tests for SARS-CoV-2 and influenza differentiation. Accelerating development and clinical evaluation of new kits.
- Lambda LifeminorSlovak company cooperating in development and manufacturing of first Slovak IVD certified PCR test for COVID-19 detection.
- ProScience TechminorSlovak company cooperating in development of first Slovak IVD certified PCR test for COVID-19 detection.
- Biomedical Center of the Slovak Academy of SciencescoreValidated COVID-19 PCR test in cooperation with team of scientists. Continued collaboration on pandemic knowledge platform and T-cell immunity detection development.
- University Science Park of Comenius University in BratislavaminorCooperated in validation of first Slovak IVD certified COVID-19 PCR diagnostic test.
- Východoslovenský onkologický ústav (Eastern Slovak Oncology Institute)coreClinical partner using Multiplex8+ for patient diagnostics. Provided testimonial on exceptional accuracy and clinical impact of test results in guiding targeted treatment decisions.
- Agel GroupcoreMajor hospital network (Mammary Center Košice-Šaca) partnering with MultiplexDX for breast cancer diagnostics. Plans to use Multiplex8+ to guide chemotherapy decisions and personalize treatment based on tumor parameters.
Scale indicators19 records
Recent moves6 records
Expansion highlights7 records
MultiplexDX competitors and assessment
Company assessmentBroad incumbents
- Veracyte:
- NeoGenomics: NeoGenomics (which acquired Inivata) is a major oncology diagnostics company offering comprehensive molecular profiling services. CMO David Eberhard previously worked at Inivata, indicating technology adjacency to MultiplexDX's liquid biopsy/molecular diagnostics capabilities.
- Exact Sciences: Exact Sciences owns Oncotype DX, the dominant gene expression test for breast cancer treatment decisions. Directly competes with Multiplex8+ in breast cancer prognostic/predictive testing with established US reimbursement and NCCN guideline inclusion.
Direct peers
- Agendia: Agendia provides MammaPrint, the leading FDA-cleared breast cancer recurrence risk test. Directly competes with Multiplex8+ in providing molecular profiling for breast cancer treatment decisions.
- NanoString Technologies: NanoString offers the Prosigna breast cancer prognostic test and nCounter/GeoMx spatial multiomics platforms that directly overlap with MultiplexDX's spatial transcriptomics approach for oncology diagnostics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
MultiplexDX social profiles
Digital presenceMultiplexDX compliance and trust
Trust signalCompliance2 records
MultiplexDX financial estimates
Financial estimateRevenue estimate
Valuation estimate
MultiplexDX leadership team
Management profileNumber of profiles
Profiles6 records
MultiplexDX funding detail
Funding detailFunding overview
Funding rounds8 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MultiplexDX M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MultiplexDX
What does MultiplexDX do?
MultiplexDX develops and delivers multiplexed molecular diagnostic products and services built on a proprietary RNA-based platform that cross-validates RNA fluorescence in situ hybridization (FISH) visualization with RNA sequencing. Its core offering, the Multiplex8+ breast cancer diagnostic test, analyzes over 20,000 protein-coding and non-coding genes from FFPE tissue samples, predicts response to 33 FDA/EMA-approved therapies, and targets 98% diagnostic accuracy. The company also sells custom oligonucleotides, provides RNA sequencing, RNA FISH, and NGS/bioinformatics services, and has developed the IVD-certified vDetect COVID-19 RT-qPCR kit.
Is MultiplexDX a public or private company?
MultiplexDX is a private company. It is classified as venture growth investor backed and is currently operating.
When was MultiplexDX founded?
MultiplexDX was founded in 2016. It employs 1 to 10 people.
Where is MultiplexDX based?
MultiplexDX is headquartered in Gaithersburg, United States, in the North America region.
How does MultiplexDX make money?
Three revenue lines are on record. Diagnostic Services are the primary driver. The others are custom Oligonucleotides and R&D Services and Grants.
Who are MultiplexDX's main competitors?
Broad incumbents on record are Veracyte, NeoGenomics and Exact Sciences. Direct peers are Agendia and NanoString Technologies.
Does MultiplexDX have an API?
No public API is recorded for MultiplexDX.
What industry is MultiplexDX in?
MultiplexDX's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.